Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineAssociation of Low-Dose Colchicine with Incidence of Knee and Hip Replacements

A Randomized, Controlled, Double-Blind Trial Analyzing Colchicine’s Role in Reducing Knee and Hip Replacement Incidences

An exploratory analysis of the LoDoCo2 randomized trial has led to a promising correlation between low-dose colchicine treatment and a reduced incidence of knee and hip replacements.

  • Colchicine (0.5 mg daily) was the focus of the study for its potential to reduce total knee replacements (TKRs) and total hip replacements (THRs).
  • The study was conducted across 43 centers in Australia and the Netherlands involving 5,522 patients with chronic coronary artery disease.
  • Two groups of 2,762 and 2,760 patients were respectively administered with colchicine and placebo over a median follow-up of 28.6 months.
  • 2.5% (68) patients in the colchicine group underwent TKR or THR, compared to 3.5% (97) in the placebo group.
  • Incidence rate was 0.90 vs. 1.30 per 100 person-years for colchicine and placebo groups, with a difference of -0.40 per 100 person-years.
  • The hazard ratio stood at 0.69 (Confidence Interval: 0.51 to 0.95), favoring colchicine.
  • This study didn’t specifically collect information on osteoarthritis, warranting further exploration into colchicine therapy for slowing osteoarthritis progression.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form